International journal of biological macromolecules
Therapeutic potential of a long-acting form of rhDNase I for the treatment of cystic fibrosis.
Antonella Grigoletto, Giulia Mori, Danila Delfino, Gloria Bizzotto, Benedetta Campara, Maria Natalia Calienni, Francesca Buttini, Stefania Glieca, Giulia Della Rosa, Tommaso Tedeschini, Rosaria Casciaro, Nicola Tirelli, Riccardo Percudani, Gianfranco Pasut
Published: 202610.1016/j.ijbiomac.2026.150145
Abstract
rhDNase I (recombinant human deoxyribonuclease I, known as Pulmozyme®) has mucolytic action, which is clinically exploited in cystic fibrosis (CF). In the lungs, its efficacy is hampered by both limited stability and presence of inhibitors such as G-…
Preview only. Read the full abstract at the source